Fortress Biotech Inc
NASDAQ:FBIO
Fortress Biotech Inc
Gross Profit
Fortress Biotech Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fortress Biotech Inc
NASDAQ:FBIO
|
Gross Profit
$57.9m
|
CAGR 3-Years
23%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Fortress Biotech Inc's Gross Profit?
Gross Profit
57.9m
USD
Based on the financial report for Dec 31, 2023, Fortress Biotech Inc's Gross Profit amounts to 57.9m USD.
What is Fortress Biotech Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
23%
Over the last year, the Gross Profit growth was 29%. The average annual Gross Profit growth rates for Fortress Biotech Inc have been 23% over the past three years , 23% over the past five years .